Osimertinib Clinical Trials
49 recruitingDrug
Phase 225Phase 116Phase 311Not Applicable1
Showing 1–20 of 49 trials
Recruiting
Phase 3
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Stage IIIB Lung Cancer AJCC v8Stage IV Lung Cancer AJCC v8Advanced Lung Non-Squamous Non-Small Cell Carcinoma+2 more
National Cancer Institute (NCI)300 enrolled604 locationsNCT04181060
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Breast CancerLung Cancer
Bristol-Myers Squibb416 enrolled61 locationsNCT06618287
Recruiting
Phase 1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
BioNTech SE320 enrolled45 locationsNCT05142189
Recruiting
Phase 2
A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer
Advanced Non Small Cell Lung Cancer (NSCLC)
Akeso348 enrolled1 locationNCT07669779
Recruiting
Phase 1Phase 2
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center66 enrolled7 locationsNCT07535437
Recruiting
Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Recurrent Lung Non-Small Cell CarcinomaAdvanced Lung Non-Small Cell CarcinomaStage IIIB Lung Non-Small Cell Cancer AJCC v7+1 more
National Cancer Institute (NCI)46 enrolled345 locationsNCT03191149
Recruiting
Phase 2Phase 3
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
AbbVie490 enrolled110 locationsNCT07155187
Recruiting
Phase 1
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
EGFR Mutation Positive Non-small Cell Lung CancerEGFR Mutated Non-small Cell Lung Cancer Patients
Nuvectis Pharma, Inc.18 enrolled6 locationsNCT07315113
Recruiting
Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Locally Advanced Lung Non-Small Cell CarcinomaStage III Lung Cancer AJCC v8Stage IIB Lung Cancer AJCC v8
NRG Oncology474 enrolled477 locationsNCT05624996
Recruiting
Phase 1Phase 2
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
Small Cell Lung Cancer ( SCLC )Transformed Small Cell Lung Cancer
Misty Shields16 enrolled1 locationNCT07153055
Recruiting
Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers
Metastatic Non Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center571 enrolled18 locationsNCT04410796
Recruiting
Phase 2
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Stage IV Lung Cancer AJCC v8Recurrent Lung Non-Small Cell Carcinoma
SWOG Cancer Research Network66 enrolled454 locationsNCT05642572
Recruiting
Phase 1Phase 2
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Non-small Cell Lung Cancer
Dizal (Jiangsu) Pharmaceutical Co., Ltd.160 enrolled17 locationsNCT07079475
Recruiting
Phase 2
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Non-small Cell Lung Cancer
Guangdong Association of Clinical Trials120 enrolled4 locationsNCT07375316
Recruiting
Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
AstraZeneca744 enrolled303 locationsNCT06417814
Recruiting
Phase 3
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
Non-small Cell Lung Cancer
Region Skane200 enrolled1 locationNCT06486142
Recruiting
Phase 1
First in Human Study of AZD9592 in Solid Tumors
Carcinoma, Non-Small Cell LungColorectal NeoplasmsHead and Neck Neoplasms+1 more
AstraZeneca403 enrolled51 locationsNCT05647122
Recruiting
Phase 2
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.60 enrolled1 locationNCT07329322
Recruiting
Phase 2
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
Stage IV Lung Cancer AJCC v8Lung Non-Small Cell Carcinoma
City of Hope Medical Center32 enrolled2 locationsNCT06014827
Recruiting
Phase 3
A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.420 enrolled2 locationsNCT06670196